Hypertension induces a variety of abnormalities such as left ventricular (LV) hypertrophy and systolic/diastolic dysfunction, eventually leading to symptomatic heart failure. 1 In addition, hypertension remains the leading cause of heart failure. 2 Sympathoexcitation plays a pivotal role in the pathophysiology of hypertension. 3 Numerous clinical and preclinical investigations have shown that treatments targeting sympathoexcitation successfully reduce blood pressure (BP) and attenuate LV hypertrophy and progression of heart failure, subsequently improving survival. [4] [5] [6] Thus, much interest has been focused on interventions targeting the sympathetic nervous system in hypertensive patients. 7, 8 The carotid body including peripheral chemoreceptors responds primarily to acute hypoxemia and increases ventilation to maintain arterial oxygen tension. 9 Stimulation of the carotid body also drives systemic sympathetic tone through direct signaling to the brain stem, and increases BP. 10 In addition, hyperactivity or hypersensitivity of peripheral chemoreflex in patients with hypertension 11,12 and heart failure 13,14 have been reported, causing excessive central sympathetic drive and poor prognosis. 14 Based on these backgrounds, carotid body denervation (CBD) has been confirmed to reduce sympathetic nerve activity (SNA) and lower BP in a rat model of hypertension, 15,16 as well as restore normal autonomic balance and improve survival in a rat model of heart failure after myocardial infarction. 17 Although the benefits of CBD for hypertension and postmyocardial infarction heart failure have been reported, how CBD impacts cardiac function and survival in hypertensive heart failure remains unknown. Evaluating the effects of CBD on hypertensive heart failure using a specific animal model is needed not only to examine the therapeutic effect of CBD but also to further understand its pathophysiology. 
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Dahl salt-sensitive rats fed 8% NaCl diet from 6 weeks of age shows progressive increase in BP and development of cardiac dysfunction, eventually leading to heart failure. 18, 19 Furthermore, Inoko et al., 19 reported that this model was appropriate to investigate hypertensive heart failure from its physiological and histological phenotype. We hypothesized that CBD decelerates or even prevents the progression of heart failure caused by hypertension, and consequently improves survival in Dahl salt-sensitive rats.
METHODS
The study was approved by the Committee on Ethics of Animal Experiment, Kyushu University Graduate School of Medical Sciences. Animal experimentation and care were conducted in strict accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health.
Five-week-old Dahl salt-sensitive rats were purchased from Japan SLC (Hamamatsu, Japan). All rats were housed in a room maintained at constant temperature (25 ± 2 °C) and light cycle (12-hour light/dark), and given water ad libitum during the entire experiment. We switched the initial low-salt diet (LS, 0.5% NaCl) to a high-salt diet (HS, 8% NaCl) at 6 weeks of age.
Protocol
We randomly assigned 7-week-old Dahl salt-sensitive rats to carotid body denervation group (CBD group, n = 31) and sham-operation group (SHAM group, n = 50). We performed bilateral CBD according to a previous report 15 with modification. Briefly, rats were anesthetized with continuous isoflurane (1-2%) inhalation. Bilateral carotid bifurcations were exposed through a midline cervical incision, and the tissues around the bifurcations including the carotid sinus nerves were removed. Sham-operated rats underwent the same surgical procedures to expose the carotid bifurcation but the surrounding tissues were left intact. To verify the success of CBD, we confirmed in some rats that the CBD procedure used in this study significantly attenuated the respiratory response to hypoxia (see Supplementary Data 1) as reported previously. 17 The animals were observed daily until the end of 16 weeks of age. Necropsy was performed in all rats that died to confirm whether heart failure had occurred.
BP, heart rate, and echocardiography
We implanted a telemetry system (TA11PA-C40, DSI, MN) and inserted the pressure sensing catheter in the abdominal aorta to record heart rate and BP in a subgroup of rats (CBD group, n = 14; SHAM group, n = 15). Transthoracic echocardiographic studies were performed at 7, 13, and 16 weeks of age with a 12-MHz transducer (Aplio MX, Toshiba, Tochigi, Japan) as described previously. 20 
Pressure-natriuresis relationship
The relationship between urinary sodium excretion and BP was examined in a subgroup of rats (CBD group, n = 6; SHAM group, n = 6) at 14 weeks of age. These rats were placed in metabolic cages for 24-hour urinary sodium excretion (24-hour U Na V) measurement. Simultaneously, BP was monitored with a telemetry system to obtain 24-hour averaged mean BP. At 14 weeks of age, rats were fed HS for 3 days, then switched to LS for 3 days. Twenty-four-hour U Na V and BP were measured consecutively at HS and LS. The steadystate data of HS and LS (from 48 to 72 hours after switching LS) were used for analysis (see Supplementary Data 2). For each rat, U Na V (mEq/day) was plotted as a function of mean BP under HS and LS. 21, 22 We approximated the pressurenatriuresis relationship with a linear function and calculated the x intercept, A (mm Hg), and the slope, B (mEq/day/mm Hg), as follows:
where (H) and (L) represent the data obtained during HS and LS, respectively.
Power spectral analysis of systolic BP
Spectral analysis of systolic BP (SBP) variability was performed using BP obtained by a telemetry system during 15 weeks of age. The beat-to-beat pulse frequencies of SBP were analyzed by the previously reported method, and 0.04-0.6 Hz was defined as low frequency (LF) and 0.6-2.4 Hz as high frequency (HF). 17 Urinary excretion of norepinephrine, creatinine, and sodium
We also collected 24-hour urinary samples using metabolic cages and measured urinary norepinephrine (uNE) excretion, which has been reported to be an indicator of SNA, 23 at 12, 14, and 16 weeks of age. Urinary norepinephrine levels were assayed by high-performance liquid chromatography at a commercial laboratory (SRL, Tokyo, Japan). At 16 weeks of age, we also assessed urine creatinine and sodium (Na) excretion.
Hemodynamics
Hemodynamic study was performed in survived rats at the conclusion of the experiment. We inserted a high-fidelity manometer-tipped catheter (SPR-320; Millar Instruments, TX) into the LV through the aortic valve and evaluated LV end-diastolic pressure (LVEDP), maximum positive dP/dt of LV pressure (+dP/dt max ), and minimum negative dP/dt of LV pressure (−dP/dt min ).
Other parameters
After hemodynamic measurements, blood was collected from the right carotid artery of 16-week-old rats. Blood samples were centrifuged at 4 °C, and plasma and serum samples were stored at -80 °C for assays. Plasma NE, serum creatinine, and Na were measured at a commercial laboratory (SRL). We quickly harvested organs (heart and lung) and measured their weights. We also evaluated creatinine clearance rate and fractional excretion of Na as parameters of renal function. 24 The hearts were fixed in 10% buffered formalin, embedded in paraffin, and cut into 5-µm sections. The sections were stained with Masson trichrome for evaluation of fibrosis and with hematoxylin-eosin for evaluation of cardiomyocytes. The areas of perivascular and interstitial fibrosis were determined as previously reported. 5 To determine the cardiomyocyte size, the cross-sectional area of cardiomyocyte was measured at the level of the nucleus. These analyses were performed using an imaging analyzer (Image J; National Institutes of Health).
Statistical analysis
All data are presented as mean ± SEM. Data were analyzed using statistical software (Survey Research Information, Tokyo, Japan). Differences between CBD and SHAM groups were assessed using the unpaired Student t-test. Differences in mean BP and U Na V under HS and LS were assessed using the paired Student t-test. Survival rates were estimated by the Kaplan-Meier method and compared by a log-rank test. P values less than 0.05 were considered statistically significant.
RESULTS
Body weight, BP, and heart rate CBD significantly maintained body weight compared to SHAM (Figure 1a) . Mean BP was similar in 2 groups until 9 weeks of age, but decreased significantly in CBD group by more than 20 mm Hg compared to SHAM group after 11 weeks of age (Figure 1b) . Heart rate was lower in CBD group than in SHAM group, and the difference was significant at 13, 15, and 16 weeks of age (Figure 1c ).
Survival
Survival rates in CBD and SHAM groups are shown in Figure 1d . CBD markedly improved the survival rate at the end of 16 weeks of age. Survival rates were 76% in CBD group and 32% in SHAM group (P = 0.001). CBD achieved a 64.8% relative risk reduction. Necropsy examination of rats that died during the observation period showed pulmonary congestion in almost all rats, and brain hemorrhage in 2 rats in SHAM group.
Assessment of sympathetic tone
Twenty-four-hour uNE excretion increased progressively during the follow-up period in both groups (Figure 2a) , and was significantly lower in CBD group than in SHAM group at all time points. On the other hand, plasma NE levels tended to decrease in CBD group at 16 weeks of age, but this change was not statistically significant (P = 0.077) (Figure 2b ).
Representative traces of the power spectral density of SBP are shown in Figure 2c . CBD significantly increased SBP-HF (P < 0.01), and decreased SBP-LF (P < 0.01) and SBP LF/HF ratio (P < 0.01) (Figure 2d ).
Pressure-natriuresis relationship
The pressure-natriuresis relationships in CBD and SHAM groups are shown in Figure 3 . U Na V did not differ between CBD and SHAM groups either under HS (18.9 ± 2.4 vs. 20.6 ± 1.4 mEq/day, N.S.) or LS (2.1 ± 0.1 vs. 2.4 ± 0.2 mEq/day, N.S.). CBD significantly reduced the x intercept compared to SHAM (168.2 ± 6.5 vs. 198.1 ± 9.8 mm Hg, P < 0.05) without changing the slope (0.87 ± 0.15 vs. 1.01 ± 0.17 mEq/day/mm Hg, N.S.), indicating a parallel leftward shift of the pressure-natriuresis relationship.
Echocardiography
As shown in Table 1 , LV end-diastolic diameter and LV end-systolic diameter were significantly lower in CBD group than in SHAM group at 16 weeks of age. Consequently, percent fractional shortening was significantly higher in CBD group than in SHAM group (34.2 ± 1.2 vs. 29.1 ± 1.3%, P < 0.01). Septal wall thickness + posterior wall thickness tended to increase in both groups.
Hemodynamics, organ weight, renal function, and histology
As shown in Table 2 , CBD reduced biventricular weight (4.2 ± 0.1 vs. 4.8 ± 0.1 g/kg, P < 0.01) compared to SHAM, indicating the prevention of cardiac remodeling. CBD also reduced lung weight, a marker of pulmonary congestion (4.7 ± 0.2 vs. 6.4 ± 0.5 g/kg, P < 0.01). There were no significant differences in parameters of renal function (serum creatinine, creatinine clearance rate, and fractional excretion of Na).
CBD significantly lowered LVEDP (5.0 ± 0.9 vs. 9.0 ± 1.4 mm Hg, P < 0.05) and −dP/dt min (−10,174 ± 624 vs. −7,231 ± 481 mm Hg/sec, P < 0.01) compared to SHAM. There was no significant difference in +dP/dt max between 2 groups (14,294 ± 1,542 vs. 12,184 ± 1,569 mm Hg/sec, P = 0.36), while +dP/dt max /LVEDP was significantly increased in CBD group (3,385 ± 561 vs. 1,391 ± 118/sec, P < 0.01).
In histological analysis ( Figure 4 and Table 2 ), CBD significantly reduced the degree of perivascular (40.3 ± 2.4 vs. 52.1 ± 1.5%, P < 0.01) and interstitial fibrosis (8.3 ± 1.3 vs. 13.8 ± 0.8%, P < 0.01) compared to SHAM. CBD also attenuated the cross-sectional area of cardiomyocytes in LV (648 ± 38 vs. 825 ± 38 µm 2 , P < 0.01).
DISCUSSION
This is the first report on the effects of CBD in a rat model of hypertensive heart failure. The major findings of this study are as follows: (i) CBD attenuated the progression of heart failure and markedly improved survival in Dahl salt-sensitive rats; (ii) CBD lowered BP without changing natriuresis, resulting in a parallel leftward shift of the pressure-natriuresis relationship; (iii) Sympathoinhibition may play an important role in the beneficial effects of CBD.
Effect of CBD on SNA and BP
Deactivation of peripheral chemoreflex by hyperoxic gas inhalation reduces SNA and BP in hypertensive subjects. 11 In addition, McBryde et al. 16 reported that CBD reduced renal SNA as shown by direct recording of nerve activity in an animal model of hypertension. Dahl salt-sensitive rat fed a high-salt diet represent severe hypertension accompanied by sympathoexcitation. 25, 26 In this study, we showed that CBD Data are expressed as mean ± SEM. *P < 0.05 vs. SHAM of the same age, † P < 0.01 vs. SHAM of the same age. We randomly selected survived rats (n = 14-35) and performed echocardiographic study. Abbreviations: CBD, carotid body denervation group; FS, fractional shortening; LVEDD, LV end-diastolic diameter; LVEF, LV ejection fraction; LVESD, LV end-systolic diameter; PWT, posterior wall thickness; SHAM, sham-operation group; SWT, septal wall thickness.
significantly reduced 24-hour uNE and SBP-LF. While these findings strongly indicate a sympathoinhibitory effect of CBD, these data have to be interpreted with caution, because they are indirect markers of SNA. On the other hand, the reduction of plasma NE did not reach statistical significance (P = 0.077). A possible reason is that while 24-hour uNE may indicate the mean level of SNA during 24 hours, plasma NE only reflects SNA at a particular point in time because the half-life of norepinephrine in plasma is only 2 to 3 minutes. 27 Taking together, we consider that our results strongly indicate that the peripheral chemoreflex may in part contribute to sympathoexcitation in Dahl salt-sensitive rats, and CBD may reduce SNA.
BP in an individual is strongly determined by the pressurenatriuresis relationship. 21, 28 Steady-state BP converges the intersection of the pressure-natriuresis relationship and the amount of sodium output/intake, despite changes in cardiac function and vascular properties. 22 In this study, we evaluated how CBD impacts the pressure-natriuresis relationship in the conscious condition. Several factors such as renal function, 29 the renin-angiotensin system 30 and the sympathetic nervous system 31 may alter the pressure-natriuresis relationship by shifting the line or changing the slope. DiBona and Esler 32 reported that renal sympathoexcitation reduces diuresis and sodium excretion by changing renin secretion, renal tubular sodium reabsorption and renal vasoconstriction, and elevates BP. Roman et al. 31 demonstrated that denervation of sympathetic nerves surrounding the renal artery (renal denervation) results in a parallel leftward shift of the pressure-natriuresis relationship without changing the slope in an acute phase experiment. Hildebrandt et al. 33 also demonstrated that chronic suppression of central sympathetic outflow by carotid baroreflex stimulation results in a parallel leftward shift of the pressure-natriuresis relationship. As shown in Figure 3 , CBD significantly shifted the pressurenatriuresis relationship leftward without changing the slope. We also confirmed that there was no significant difference in renal function between CBD and SHAM groups.
Beneficial effects of CBD on hypertensive heart failure As summarized in Tables 1 and 2 , CBD significantly inhibited LV dilatation and deterioration of percent fractional shortening, and increased +dP/dt max /LVEDP compared to SHAM in 16-week-old Dahl salt-sensitive rats. These results indicate that CBD attenuates worsening of cardiac systolic function. Furthermore, CBD improved −dP/dt min , an index of LV relaxation, compared to SHAM. Previous studies in hypertensive heart failure rat models demonstrated that sympathoinhibition induced by telmisartan and moxonidine The effect of carotid body denervation on organ weights (n = 21-22), hemodynamics (n = 7), renal function (n = 14-22), and histology (n = 5-8). Organ weights and CCr are normalized by body weight in each rat. Data are expressed as mean ± SEM. *P < 0.05, † P < 0.01 vs. SHAM. Abbreviations: BW, body weight; CBD, carotid body denervation group; CCr, creatinine clearance rate; +dP/dt max , maximum positive dP/dt of left ventricular pressure; −dP/dt min , minimum negative dP/dt of left ventricular pressure; FE Na , fractional excretion of Na; LVEDP, left ventricular end-diastolic pressure; SHAM, sham-operation group.
reduced cardiac fibrosis and improved survival independent of the BP-lowering effect. 4, 5 Our study also showed that CBD reduced LV fibrosis and prevented hypertrophy of cardiomyocytes ( Figure 4 and Table 2 ). Although we were not able to differentiate between direct sympathoinhibitory effect and indirect effect mediated by BP decrease, sympathoinhibition may be an important mechanism that attenuates LV fibrosis, hypertrophy, and remodeling. Furthermore, our findings that CBD markedly improved survival with a 64.8% relative risk reduction (Figure 1d ) accompanied by decrease in LVEDP (Table 2 ) and improvement of cardiac function indicate that CBD reduces heart failure death in Dahl saltsensitive rats. SHAM group showed a cumulative survival rate of 32% at 16 weeks of age, almost the same as in a previous report. 18 Del Rio et al. 17 reported that CBD prevented cardiac remodeling and improved survival in a rat model of post-myocardial infarction. We demonstrated that CBD was also effective in Dahl salt-sensitive rats as a hypertensive heart failure model. We speculate that both in patients and animal models, CBD is an effective treatment for cardiovascular diseases which are aggravated by peripheral chemoreflex hypersensitivity or hyperactivity.
Clinical implications
Our results and previous investigations suggest that CBD is potentially an effective neuromodulatory therapy, which could exert prolonged sympathoinhibitory effect, in hypertensive heart failure. In addition, sympathoinhibition by CBD may attenuate damage not only in the heart but also in the kidney and peripheral vasculature. 10 On the other hand, some issues should be addressed in further development of CBD for clinical application. CBD is an invasive treatment that requires surgical intervention. Although a few case reports have suggested safety of this procedure in patients with heart failure, 34 whether such an invasive procedure is tolerable for heart failure patients remains to be confirmed. Moreover, CBD blocks the function of peripheral chemoreceptors which are responsible for respiratory homeostasis. Thus, loss of response to hypoxia due to loss of peripheral chemoreceptors would be a theoretical concern. Due to such potential limitations of CBD in patients with heart failure, it is not possible to extrapolate the favorable preclinical evidence to clinical application of CBD at the present stage, as noted by Johnson and Joyner. 35 
Limitations
This study has several limitations. First, since baroreceptors that sense BP are located in the carotid bifurcations, the CBD procedure has a risk of injuring nerves in the carotid baroreflex. However, in this study, we demonstrated that CBD improved autonomic balance as assessed by power spectral analysis of SBP. Furthermore, we showed that BP variability, an indirect index of baroreflex function, 36 was not significantly different between CBD and SHAM groups (see Supplementary Data 3). Despite these preliminary data suggesting no major disturbance of baroreflex function by CBD, more detailed study is required. Second, to verify the feasibility and the maximum effect of treating hypertensive heart failure by CBD, we performed CBD at 1 week after initiating HS, which was the prehypertensive phase. In the clinical setting, most patients develop heart failure subsequent to prolonged established hypertension. However, Dahl salt-sensitive rats used in this study developed cardiac dysfunction and heart failure in parallel with increases in BP (11-14 weeks). In spontaneous hypertensive rats, CBD has been shown to reduce BP when performed in both prehypertensive (4 weeks of age) and established hypertensive phases (12 weeks of age), 15 but it takes around 2 years to observe heart failure. 37 We thus need to develop an appropriate animal model to mimic the clinical course of hypertensive heart failure for the evaluation of clinical feasibility of CBD.
In conclusion, in Dahl salt-sensitive rats fed a high-salt diet, we demonstrated that CBD attenuated the progression of hypertension as demonstrated by a leftward shift of the pressure-natriuresis relationship and prevented the progression of heart failure, consequently markedly improved survival. Sympathoinhibition is a possible mechanism by which CBD exerts the beneficial effects.
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